0001461859-19-000007.txt : 20190430 0001461859-19-000007.hdr.sgml : 20190430 20190429175425 ACCESSION NUMBER: 0001461859-19-000007 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190430 DATE AS OF CHANGE: 20190429 EFFECTIVENESS DATE: 20190430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVENTRIX INC CENTRAL INDEX KEY: 0001283259 IRS NUMBER: 200372415 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-293763 FILM NUMBER: 19777401 BUSINESS ADDRESS: STREET 1: 12647 ALCOSTA BLVD. STREET 2: SUITE 400 CITY: SAN RAMON STATE: CA ZIP: 94583 BUSINESS PHONE: 925-830-1000 MAIL ADDRESS: STREET 1: 12647 ALCOSTA BLVD. STREET 2: SUITE 400 CITY: SAN RAMON STATE: CA ZIP: 94583 FORMER COMPANY: FORMER CONFORMED NAME: CHF TECHNOLOGIES INC DATE OF NAME CHANGE: 20040310 D/A 1 primary_doc.xml X0708 D/A LIVE 0001283259 BIOVENTRIX INC 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 925-830-1000 DELAWARE CHF TECHNOLOGIES INC Corporation true KENNETH MILLER 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Executive Officer Director MICHAEL TAGLICH 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director STEVEN HEALY 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director PAUL SEID 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director WARREN PINKERT II 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director GEORGE FAZIO 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director ROBERT TAGLICH 12647 ALCOSTA BLVD. 94583 SAN RAMON CA CALIFORNIA 94583 Director MARK RAVICH 12647 ALCOSTA BLVD. SUITE 400 SAN RAMON CA CALIFORNIA 94583 Director Other Decline to Disclose 06b true 0001461859-19-000003 2017-08-25 true true false 0 TAGLICH BROTHERS, INC. 29102 None None 790 NEW YORK AVENUE SUITE 209 HUNTINGTON NY NEW YORK 11743 All States false 40000000 21778700 18221300 false 158 3200000 true 0 Placement Agent also to receive warrants to purchase Series A-1 Preferred Stock equal to 10% of the number of shares of Common Stock the Notes are convertible into at an exercise price of $7.50 per share. 800000 true false BIOVENTRIX INC /s/Kenneth Miller Kenneth Miller CEO 2019-04-29